Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonalcoholic steatohepatitis (NASH) – current treatment recommendations and future developments
Elke Roeb, Andreas Geier
Zeitschrift für Gastroenterologie (2019) Vol. 57, Iss. 04, pp. 508-517
Closed Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment
Xiangyu Guo, Xunzhe Yin, Zuojia Liu, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 15489-15489
Open Access | Times Cited: 180
Efficacy of a 2-Month Very Low-Calorie Ketogenic Diet (VLCKD) Compared to a Standard Low-Calorie Diet in Reducing Visceral and Liver Fat Accumulation in Patients With Obesity
Guilherme Moura Cunha, Germán Guzmán, Livia Lugarinho Correa De Mello, et al.
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 98
Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)
Paria Zarghamravanbakhsh, Michael Frenkel, Leonid Poretsky
Metabolism Open (2021) Vol. 12, pp. 100149-100149
Open Access | Times Cited: 87
Deep learning enables pathologist-like scoring of NASH models
Fabian Heinemann, Gerald Birk, Birgit Stierstorfer
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 79
Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025
Elke Roeb, Ali Canbay, Frank Tacke, et al.
Zeitschrift für Gastroenterologie (2022) Vol. 60, Iss. 09, pp. 1346-1421
Open Access | Times Cited: 53
Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
Marija Branković, Igor Jovanović, Marija Dukić, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 5146-5146
Open Access | Times Cited: 41
Nanoparticles and siRNA: A new era in therapeutics?
María Dolores Pérez‐Carrión, Inmaculada Posadas, Valentı́n Ceña
Pharmacological Research (2024) Vol. 201, pp. 107102-107102
Open Access | Times Cited: 15
New Therapeutic Approaches for the Treatment of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Increased Cardiovascular Risk
Marija Branković, Marija Dukić, Tijana Gmizić, et al.
Diagnostics (2024) Vol. 14, Iss. 2, pp. 229-229
Open Access | Times Cited: 11
Gut Microbiome and Organ Fibrosis
Carolina F. F. A. Costa, Benedita Sampaio‐Maia, Ricardo Araújo, et al.
Nutrients (2022) Vol. 14, Iss. 2, pp. 352-352
Open Access | Times Cited: 36
Induction of autophagy via the PI3K/Akt/mTOR signaling pathway by Pueraria flavonoids improves non-alcoholic fatty liver disease in obese mice
Chunbin Sun, Jin Zhang, Jiong Hou, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 157, pp. 114005-114005
Open Access | Times Cited: 36
Atractylodin alleviates nonalcoholic fatty liver disease by regulating Nrf2-mediated ferroptosis
Qing-Yan Ye, Yun Jiang, Di Wu, et al.
Heliyon (2023) Vol. 9, Iss. 7, pp. e18321-e18321
Open Access | Times Cited: 17
Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease
Jakub Rochoń, Piotr Kalinowski, Ksenia Szymanek-Majchrzak, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 23, pp. 2964-2980
Open Access | Times Cited: 7
Non‐alcoholic fatty liver disease and psoriasis – is there a shared proinflammatory network?
Johanna Heitmann, Verena Frings, Andreas Geier, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2021) Vol. 19, Iss. 4, pp. 517-528
Open Access | Times Cited: 35
LILRB2/PirB mediates macrophage recruitment in fibrogenesis of nonalcoholic steatohepatitis
Danpei Li, Li Huang, Ran-Ran Kan, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 15
Cannabinoid receptor 1 knockout alleviates hepatic steatosis by downregulating perilipin 2
Karuna Irungbam, Y Churin, Tomomitsu Matono, et al.
Laboratory Investigation (2019) Vol. 100, Iss. 3, pp. 454-465
Open Access | Times Cited: 36
Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD)
Elke Roeb
Visceral Medicine (2021) Vol. 37, Iss. 4, pp. 273-280
Open Access | Times Cited: 29
Does Schistosoma Mansoni Facilitate Carcinogenesis?
Verena von Bülow, Jakob Lichtenberger, Christoph G. Grevelding, et al.
Cells (2021) Vol. 10, Iss. 8, pp. 1982-1982
Open Access | Times Cited: 27
Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – April 2022 – AWMF Registration No.: 021–025

Zeitschrift für Gastroenterologie (2022) Vol. 60, Iss. 09, pp. e733-e801
Open Access | Times Cited: 21
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar, Omar Khaznadar, Ana G. Petrovic, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 7, pp. 6300-6314
Open Access | Times Cited: 4
S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion
Sabrina Groß, Michael Bitzer, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 02, pp. e82-e158
Closed Access
S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Langversion
Michael Bitzer, Sabrina Groß, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 03, pp. e159-e260
Closed Access
Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis
Zobair M. Younossi, Linda Henry
Endocrine Practice (2021) Vol. 28, Iss. 2, pp. 204-213
Closed Access | Times Cited: 24
The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review
Andrew Ndakotsu, Govinathan Vivekanandan
Cureus (2022)
Open Access | Times Cited: 18
Attenuation by Time-Restricted Feeding of High-Fat and High-Fructose Diet-Induced NASH in Mice Is Related to Per2 and Ferroptosis
Yan-Yun Shu, Wenkang Gao, Huikuan Chu, et al.
Oxidative Medicine and Cellular Longevity (2022) Vol. 2022, pp. 1-20
Open Access | Times Cited: 18
Caveolin-1 ameliorates acetaminophen-aggravated inflammatory damage and lipid deposition in non-alcoholic fatty liver disease via the ROS/TXNIP/NLRP3 pathway
Xiangfu Jiang, Yu Li, Dongdong Fu, et al.
International Immunopharmacology (2022) Vol. 114, pp. 109558-109558
Closed Access | Times Cited: 17
Page 1 - Next Page

Scroll to top